In The News
Child removal class actions launched against NSW, WA
Law firm Cornwalls hits back at $4.8M negligence suit by former client
Top silk to join NSW Supreme Court
NAB accused in suit of rescinding job offer to pregnant employee
Slater & Gordon denies firing HR head for reporting underpayments
Wealth guru Dominique Grubisa pleads ignorance in appeal of $6M penalty
Court finds former Orix boss engaged in fraud, throws out suit against Chubb
Cruise operators face potential class action over onboard gambling
Class action dropped against Westpac unit, applicant to get $1.5M costs
Former Tabcorp CEO was forced to resign, FWC finds
Please login to bookmarkClose

Samsung Bioepis can’t get indemnity costs from Janssen Biotech after it surrendered patents for Crohn’s disease drug Stelara and filed a fresh case based on new patents for the drug. 

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?
error: The content is secured.

For information on rights and reprints, contact subscriptions@lawyerly.com.au